Exquisitely Selective MET Inhibitor Shows Promising Antitumor Activity

Strategic Insights -

SGX523, a novel ATP-competitive kinase inhibitor, has been shown to exhibit exquisite selectivity for the MET receptor tyrosine kinase, making it a promising tool for cancer research. Researchers report that SGX523 potently inhibits MET with an IC50 of 4 nmol/L, demonstrating 1,000-fold selectivity versus other protein kinases tested in biochemical assays. Crystallographic studies reveal that SGX523 stabilizes MET in a unique inactive conformation, explaining its selectivity. In vivo studies have confirmed the antitumor activity of SGX523, with dose-dependent inhibition of tumor xenografts derived from human glioblastoma, lung, and gastric cancers.

Key Takeaways:

  • SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
  • The MET receptor tyrosine kinase has emerged as an important target for cancer therapeutics, with activation linked to various cancer types, including kidney, gastric, and lung cancers.
  • SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concentrations without affecting signaling dependent on other protein kinases.
  • Crystallographic studies revealed that SGX523 stabilizes MET in a unique inactive conformation, explaining its selectivity.
  • In vivo studies confirmed the antitumor activity of SGX523, with dose-dependent inhibition of tumor xenografts derived from human glioblastoma, lung, and gastric cancers.
  • SGX523 is the most selective inhibitor of MET catalytic activity described to date, making it a useful tool for investigating the role of MET kinase in cancer.
  • The study highlights the potential of MET inhibitors as a promising approach for cancer treatment, particularly in cases where MET is implicated in tumor growth.

Sources:

  • Buchanan SG, et al. "SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo." Molecular Cancer Therapeutics, 2009;8(12):3181-90.
  • Drug Development. See also: Buchanan SG, et al. (2009).